Q-omics provides the consensus-scored KRT79 profile across patient tissues and cancer cell-line models. KRT79 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT79 is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, KRT79 RNA expression shows 9,759 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, LUAD, and ESCA as cancer lineages where KRT79 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT79 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT79 survival associations across molecular data types. KRT79 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT79 RNA expression–survival associations across cancer types. High KRT79 expression shows unfavorable associations in KIRC, ACC, BLCA, LIHC, KICH and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT79 RNA expression.
This table summarizes KRT79 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for KRT79. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT79 shows lower tumor expression in LUAD, BRCA and LUSC and higher tumor expression in BLCA, THCA and UCEC. The LUAD box plot shows higher KRT79 RNA expression in normal versus tumor tissue (log2 FC = −1.064, t-test p < 0.001).
This table shows molecular features associated with KRT79 in patient tissues and cancer cell lines. In patient samples, KRT79 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT79 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
